Mod­er­na CEO Stéphane Ban­cel out­lines a prospec­tive moth­er­lode of Covid-19 vac­cine rev­enue — will a back­lash fol­low?

Mod­er­na shows no sign of slow­ing down, or turn­ing char­i­ta­ble when it comes to pric­ing sup­plies of its Covid-19 vac­cine.

One of the lead­ers in the Phase III race to get a Covid-19 vac­cine across the fin­ish line in record time, Mod­er­na says it’s on track to com­plete en­roll­ment in one of the most avid­ly watched stud­ies in the world next month. And the biotech has al­ready banked some $400 mil­lion in de­posits for vac­cine sup­ply as it works through ne­go­ti­a­tions with coun­tries around the world — as CEO Stéphane Ban­cel sets out to hire a com­mer­cial team.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER